Prof. Shixiong Liang 梁世雄
Chief Physician, Professor
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive cancer treatment with a focus on radiation therapy.
Dr. Liang holds a MD from Fudan University and serves as Department Chair at Guangxi Medical University Cancer Hospital. Previously Director of Radiation Therapy at Shanghai Pulmonary Hospital, Tongji University, Dr. Liang has over 20 years of experience in clinical practice, teaching, and research. The doctor has published more than 20 papers and received the Chinese Medical Award and the Second Prize of the Shanghai Science and Technology Award.
Professional roles
- Member, Radiation Therapy Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Non-Small Cell Lung Cancer Committee, CSCO
- Standing Committee Member, Radiation Therapy Committee, Wu Jieping Medical Foundation
- Editorial Board Member, Chinese Journal of Cancer Control and Prevention
Name order: in Chinese the family name comes first (Liang Shixiong). Papers usually list the name as Shixiong Liang or Liang S.
Selected publications
40 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Tissue Cell, 2026 (senior author): Integrative multi-omics profiling implicates purine metabolism and the PI3K-Akt pathway in radiation-induced lung injury. PubMed 41581409
- Radiat Oncol, 2026 (senior author): Radiation-induced hepatic toxicity from radiotherapy plus immune checkpoint inhibitors with targeted therapy in HCC patients: a propensity score-matched study. PubMed 41761241
- Immunotargets Ther, 2025 (senior author): Clinical Outcomes and Hepatic Toxicity of Combined Intensity Modulated Radiotherapy and PD-1 Inhibitors in Child-Pugh Class B Advanced Hepatocellular Carcinoma. PubMed 40964504
- Eur J Med Res, 2025 (senior author): Prognostic nomogram for hepatocellular carcinoma with major vascular invasion: a population-based study from the SEER database and a Chinese cohort. PubMed 40903746
- J Inflamm Res, 2025 (senior author): Dynamic Neutrophil-to-Lymphocyte Ratio at 3-4 weeks of Intensity-Modulated Radiotherapy Combined with Normal Liver Volume Predicts Radiation-Induced Hepatic Toxicity in Hepatocellular Carcinoma: A Retrospective Study. PubMed 40546400
- Drug Dev Res, 2025 (senior author): Dihydroartemisinin Attenuates Radiation-Induced Lung Injury by Inhibiting the cGAS/STING/NF-κB Signaling Pathway. PubMed 40285509
- Front Oncol, 2024 (senior author): Prognostic nomogram of overall survival for radiation therapy in hepatocellular carcinoma: a population study based on the SEER database and an external cohort. PubMed 39286027
- Jpn J Clin Oncol, 2024 (senior author): Development and validation of a nomogram for radiation-induced hepatic toxicity after intensity modulated radiotherapy for hepatocellular carcinoma: a retrospective study. PubMed 38376811
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion